Sumitomo Mitsui Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $138 Billion
- Q1 2025
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 2,825,361 shares of NTLA stock, worth $38.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,825,361
Previous 2,992,663
5.59%
Holding current value
$38.1 Million
Previous $34.9 Million
42.43%
% of portfolio
0.01%
Previous 0.02%
Shares
25 transactions
Others Institutions Holding NTLA
# of Institutions
339Shares Held
98.3MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$176 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$145 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$129 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$60.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$51.3 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.03B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...